Summary
Introduction
Lev Pharmaceuticals is a development stage biopharmaceutical company engaged in developing and commercializing therapeutics based on C1-esterase inhibitor (C1-INH) for the treatment of inflammatory diseases. Cinryze, the company's lead drug candidate, is being developed for acute and prophylactic treatment of hereditary angioedema (HAE).
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Lev Pharmaceuticals in-licensed C1-INH from Sanquin in 2004. C1-INH is a human plasma protein that mediates inflammation and coagulation. Besides the current pipeline candidates, Lev Pharmaceuticals is also studying the use of C1-INH in the treatment of other inflammation-linked diseases such as gram-negative septicemia, inflammatory bowel disease, Alzheimer's disease and stroke. The company did not record revenues during the period 2002-2006 because the company currently does market any products, and has no other source of revenues. Lev Pharmaceuticals forecasts to derive 100% of its revenues from the sales of Cinryze. The total revenues will grow from $43 million in 2008 to $143 million in 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
